Evaluation of beta-lactose, PVP K12 and PVP K90 as excipients to prepare piroxicam granules using two wet granulation techniques.
The present investigation aimed at evaluating the use of different excipients, beta-lactose and polyvinylpyrrolidone of two molecular weights (PVP K12 and PVP K90), in the production of improved release piroxicam granules, by wet granulation using both water and steam as granulation liquid. The formulations examined were: piroxicam (Px)/beta-lactose; Px/PVP K12 and Px/PVP K90, each one at a 1:9 weight ratio. The most significant difference between beta-lactose and PVP is that, using the first excipient, both steam and water granules were produced while, when PVP were employed, only steam granules were obtained. Image analysis revealed that beta-lactose steam granules had a larger surface area with respect to water granules, whereas lower values of this parameter were observed in PVP-s granules, confirming the Scanning Electron Microscopy micrographs and the fractal analysis results. As regards the enhancement of the dissolution profiles, the best result was obtained using beta-lactose steam granules followed by PVP K12 ones, even if the reactive dimension values indicated that during the dissolution process PVP K12 granules modified the surface more than beta-lactose granules. As regards PVP K90, this excipient was the one less influencing the granule morphology and the dissolution behaviour. Differential Scanning Calorimetry analysis suggested the partial amorphisation of the drug in the granules containing the three excipients. This result was then confirmed by X-ray powder diffraction analysis. Therefore, beta-lactose and PVP K12 could be proposed as useful excipients to enhance the dissolution rate of Px from granules prepared using the steam granulation technique.
Albertini
Beatrice
B
Dipartimento di Scienze Farmaceutiche, Università di Bologna, Bologna, Italy. beatrice@biofarm.unibo.it
Cavallari
Cristina
C
Passerini
Nadia
N
González-Rodríguez
M L
ML
Rodriguez
Lorenzo
L
D004353:Drug Evaluation, Preclinical / Q000379:methods; D005079:Excipients / Q000032:analysis / Q000737:chemistry*; D007785:Lactose / Q000031:analogs & derivatives* / Q000032:analysis / Q000737:chemistry*; D010316:Particle Size; D010894:Piroxicam / Q000032:analysis / Q000138:chemical synthesis*; D011108:Polymers / Q000032:analysis / Q000737:chemistry; D011205:Povidone / Q000032:analysis / Q000737:chemistry*; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods*
D005079:Excipients; D011108:Polymers; D010894:Piroxicam; D011205:Povidone; D007785:Lactose